Mounjaro is the brand name for injectable tirzepatide manufactured by Eli Lilly. It is FDA-approved to improve blood-sugar control in adults and in children 10 and older with type 2 diabetes (the pediatric use was added in December 2025) and, since August 2026, to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for them (prescribing information (external link)). It's dosed weekly and acts as a dual agonist on both GLP-1 and GIP receptors. It shares its active ingredient with Zepbound, which is approved specifically for weight management.
Mounjaro
Eli Lilly's brand name for injectable tirzepatide, FDA-approved for type 2 diabetes (adults and children 10+) and for cardiovascular risk reduction in high-risk adults with type 2 diabetes.
Updated Sep 26, 2026
Was this helpful?
Revision history
Last updated · 2 revisions recorded.
Show what changed
- v2
Summary rewritten; Body revised; Metadata updated
- v1
Existing article recorded at the start of version history
Improve this page
Community notes
Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.
Loading notes…
New submissions are currently paused. Existing approved notes remain available.
Related terms
- Hazard ratio — A statistic from clinical trials that compares how often an event happens over time in one group versus another; below 1 means a lower rate in the treated group.
- Sharps container — A puncture-resistant container for safely collecting used needles, pen needles, and syringes until they can be disposed of according to local rules.
- Oral semaglutide — Semaglutide taken as a once-daily pill instead of a weekly injection: Rybelsus and its reformulation, Ozempic tablets, for type 2 diabetes, and the Wegovy pill for weight management.
Related guides
- Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis — GLP-1 medications slow the stomach, but the trials show the effect is smaller and fades more than most people assume, especially with the long-acting weekly drugs. This guide covers how much slower, whether it lasts, how gastric emptying is measured, how it differs from gastroparesis, and why the "food ferments in your stomach" claim has no evidence behind it.
- Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration — Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
- Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo — There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.